Phase 3 Clinical Trials With Primary Completion Dates in May 2019
This is a list of Phase 3 trials with primary completion dates in May 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| DCPH | Deciphera Pharmaceuticals, Inc. | 2019-05-01 | Phase 3 | NCT03353753 | Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies |
| GRFS | Grifols, S.A. | 2019-05-01 | Phase 3 | NCT02806986 | Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency |
| SNY | Sanofi | 2019-05-01 | Phase 3 | NCT03351478 | Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin |
| SNY | Sanofi | 2019-05-01 | Phase 3 | NCT03066830 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin |
| SNY | Sanofi | 2019-05-01 | Phase 3 | NCT02926937 | Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy |
| SNY | Sanofi | 2019-05-01 | Phase 3 | NCT01957436 | A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer |
| SRPT | Sarepta Therapeutics, Inc. | 2019-05-01 | Phase 3 | NCT02255552 | Study of Eteplirsen in DMD Patients |
| VSTM | Verastem, Inc. | 2019-05-01 | Phase 3 | NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07 |